UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number: 001-41661
Jin Medical International Ltd.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Press Release
On January 21, 2026, Jin Medical International
Ltd. (Nasdaq: ZJYL) (the “Company”) published a press release entitled “Jin Medical International Ltd. Management
Plans For Fireside Chat”, a copy of which is attached hereto as Exhibit 99.1.
The information in this Report of Foreign Private
Issuer on Form 6-K, including the information in the press release furnished herein, shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the
liabilities of that section, and shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities
Act of 1933, as amended, except in the event that the Company expressly states that such information is to be considered filed under
the Exchange Act or incorporates it by specific reference in such filing.
EXHIBIT INDEX
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated January 21, 2026 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Jin Medical International Ltd. |
| |
|
|
| Date: January 21, 2026 |
By: |
/s/ Erqi Wang |
| |
|
Erqi Wang |
| |
|
Chief Executive Officer |
Exhibit 99.1
Jin Medical International Ltd. Management Plans
For Fireside Chat
Changzhou, China, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Jin Medical
International Ltd. (NASDAQ: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the “Company”), a NASDAQ-listed
leading provider of rehabilitation medical equipment in China, announced today that members of its management team will host a fireside
chat on February 1, 2026, to provide an update on the Company’s strategic priorities and capital structure considerations.
During the discussion, the management team will
address recent market developments and outline the framework of the Company’s ongoing strategic planning efforts. The fireside chat
is intended to offer transparency into management’s thinking and decision-making process during this period.
The Company continues to maintain what management
believes to be a strong liquidity position and is actively evaluating a range of strategic options intended to enhance its competitive
position in the industry. Management believes that these efforts are being undertaken from a position of operational and financial strength.
About Jin Medical International Ltd.
Founded in 2006 and headquartered at Changzhou,
Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with
disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately
230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing
a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and
more than 20 international distributors. The majority of Jin Medical’s wheelchair products, with more than 30 models, are sold to
distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic.
For more information, please visit: http://www.zhjmedical.com.
Forward-Looking Statement
This press release contains forward-looking statements
as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives,
goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical
facts. When the Company uses words such as “may”, “will”, “should”, “intend”, “plan”,
“strive”, “believe”, “expect”, “anticipate”, “project”, “estimate,”
or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements
are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from
the Company’s expectations discussed in the forward-looking statements.
These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to
achieve its goals and strategies, the Company’s future business development and plans for future business development, including
its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition
and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business
conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with
the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place
undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings
with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The
Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after
the date hereof.
For more information, please contact:
ir@zhjmedical.com
